Shows
Small Stocks, Big MoneyConnect Biopharma CEO Barry Quart: Targeting a $5B+ Market with a Next-Gen Asthma & COPD Therapy🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes.In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety.✅ The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies.✅ Key upcoming catalysts: topline data from Phase 2 acute studies in 1H 2026 and pharmacology results expected by early next year.✅ CNTB’s strong cash position...
2025-11-1108 minSmall Stocks, Big MoneyForemost Clean Energy CEO on Nuclear's Resurgence & 330K Acre Uranium PortfolioForemost Clean Energy (Nasdaq: FMST) is a rapidly growing North American uranium exploration holding an option to earn up to a 70% interest in 10 underexplored properties from Denison Mines. The portfolio spans over 330,000 acres within a prospective area of the Athabasca Basin surrounded by high-grade deposits. Driven by the resurgent Nuclear Renaissance, Foremost is dedicated to realizing the full potential of its projects, actively exploring in collaboration with Denison. Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec.Foremost Clean Energy is a client of RedChip. Visit...
2025-09-0908 minSmall Stocks, Big MoneyPhoenixEV CEO John Walsh Interview: 2025 Goals, $200M Backlog and Transit GrowthPhoenix Motor (OTC: PEVMD) is a pioneer and emerging leader in the electric vehicle (“EV”) industry, designing, building, and integrating electric drive systems and manufacturing heavy-duty transit buses and medium- and light- duty commercial EVs. Phoenix operates two primary brands, PhoenixEV, focused on commercial products including heavy and medium duty EVs (transit buses, shuttle buses, school buses and delivery trucks, among others) and EdisonFuture, which intends to serve international markets, particularly Latin America and Caribbeans region.Phoenix is capitalizing on a robust market opportunity backed by significant federal and state regulatory mandates. With a commanding market share in the tran...
2025-08-2607 minSmall Stocks, Big MoneyInside 60 Degrees Pharmaceuticals: CEO Geoffrey Dow on Revenue Growth & Pipeline Potential60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60 Degrees Pharmaceuticals is a client of RedChip. Visit www.redchip.com/stocks/SXTP to learn more.
2025-08-1908 minSmall Stocks, Big MoneyInvestor Insights: Calidi CEO Eric Poma Discusses Breakthroughs in Oncolytic VirotherapyCalidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even p...
2025-08-0509 minSmall Stocks, Big MoneyPrecision Oncology at Scale: Lantern Pharma’s Strategic Vision with CEO Panna SharmaLantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefining oncology drug development through artificial intelligence. Its proprietary RADR® platform leverages over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%, respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC in never-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressive B-cell lymphomas. The company also advances CNS oncology programs via its subsidiary Starlight Therapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with global partn...
2025-07-2917 minSmall Stocks, Big MoneyInside Atossa Therapeutics: CEO Dr. Steven Quay Talks Pipeline, Progress, and Investor OutlookAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is strategically prioritizing metastatic breast cancer, where (Z)-endoxifen has shown encouraging clinical activity, favorable tolerability, and potential to address endocrine resistance through dual targeting of ERα and PKCβ1. With multiple Phase 2 trials completed, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Atossa Therapeutics is a client of RedChip. Vi...
2025-07-2205 minSmall Stocks, Big MoneyInside Processa Pharma: CEO George Ng on Disrupting Oncology Drug DevelopmentProcessa Pharmaceuticals (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies, resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa's strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.Processa is a client of RedChip. Visit...
2025-07-1510 minSmall Stocks, Big MoneyGreenwich LifeSciences' CEO on Advancing HER2+ Immunotherapy | Phase III Insights & StrategyGreenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or “over-expressor”) levels.Greenwich LifeSciences is a client of RedChip. Visit RedChip.com/stocks/GLSI to learn more.
2025-07-0820 minSmall Stocks, Big MoneyASP Isotopes CEO Paul Mann on Transforming Global Isotope Supply for Medicine, Clean Energy, & More!ASP Isotopes is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing.ASP Isotopes is a client of RedChip. Visit www.redchip.com/stocks/aspi to learn more.
2025-06-2406 minSmall Stocks, Big MoneyEnlivex CEO on Revolutionizing Osteoarthritis Therapy with Allocetra™ | Investor Deep DiveEnlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.Enlivex Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/enlv to learn more.
2025-06-1708 minSmall Stocks, Big MoneyUranium & Lithium Boom: Foremost Clean Energy CEO on the Future of North America's SupplyForemost Clean Energy Ltd. (Nasdaq: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at...
2025-06-0307 minSmall Stocks, Big MoneyFatPipe (Nasdaq: FATN) CEO Talks Profitability, Patented Tech & Global Growth StrategyFatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity. The company develops and markets enterprise-class software solutions—including Software-Defined Wide Area Networking (SD-WAN), Secure Access Service Edge (SASE), and Network Monitoring Services (NMS)—that enable customers to unify, secure, and optimize their digital infrastructure across cloud, hybrid, and on-premise environments.FatPipe serves over 2,500 end-user customers worldwide across sectors such as government, healthcare, finance, education, and retail, with its largest customer bases in the U.S. and India. The company’s patented technology allows for intelligent traffic failover, enhanced security, simplified networ...
2025-05-2706 minSmall Stocks, Big MoneyBioVie CEO Cuong Do on Alzheimer’s Breakthroughs, Liver Disease Pipeline & What’s AheadBioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more.
2025-05-2005 minSmall Stocks, Big MoneyInside ConnectM: How AI Is Powering the $2 Trillion Electrification BoomConnectM Technology Solutions (Nasdaq: CNTM) is enabling a faster, smarter transition to an all-electric future through its AI-driven energy intelligence platform. The company integrates electrified energy assets with proprietary technology solutions, enabling residential, commercial, and transportation customers to efficiently transition from fossil fuels to renewable energy sources. With 120,000+ connected assets and growing, ConnectM is uniquely positioned in the rapidly expanding $2 trillion electrification market. Operating across Building Electrification, Distributed Energy, and Transportation & Logistics segments, ConnectM provides high-margin, scalable solutions, including AI-powered heat pumps, EV solutions, and smart energy management. Backed by a history of 20 consecutive quarters of revenue growth, a...
2025-04-2909 minSmall Stocks, Big MoneybioAffinity (Nasdaq: BIAF) CEO Maria Zannes Talks CyPath® Lung, Growth & AI InnovationbioAffinity Technologies (Nasdaq: BIAF) addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis and broad-spectrum cancer treatments. Lung cancer is the leading cause of cancer-related deaths. The Company’s first product, CyPath® Lung, improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. CyPath® Lung, a laboratory developed test (LTD), is patient-friendly and physician focused. Physicians order CyPath® Lung for their patients after lung cancer screening or other imaging reveals a suspicious finding.Patients collect their sample at home and ship overnight in a pre-paid envelope to the C...
2025-04-2211 minSmall Stocks, Big MoneyInterview with Connect Biopharma CEO Barry Quart | Transforming Acute Asthma & COPD CareConnect Biopharma Holdings Ltd. (Nasdaq: CNTB) is a clinical-stage biotechnology company advancing innovative therapeutics designed to transform the treatment landscape for inflammatory diseases driven by T-cell dysfunction. The company’s lead candidate, rademikibart, is a next-generation, highly differentiated monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), with potential applications in asthma and chronic obstructive pulmonary disease (COPD)—markets collectively representing multi-billion-dollar commercial opportunities. Backed by robust clinical data from a global Phase 2 study demonstrating superior efficacy, rapid onset of action, and a favorable safety profile, Connect is strategically positioned to enter clinical trials targeting acute exacerbations in respiratory diseases, an ar...
2025-04-1508 minSmall Stocks, Big MoneyBullFrog AI CEO Vin Singh on Revolutionizing Drug Development with AI-Powered InsightsBullFrog AI, a US-company headquartered in Maryland, is revolutionizing drug discovery and development with BullFrog Data Networks®, a cutting-edge platform powered by its proprietary bfLEAP® technology. Designed for small and mid-sized biopharma companies, BullFrog Data Networks® enables users to harness high-dimensional, multi-modal datasets, uncovering hidden relationships and pathways to accelerate target identification, clinical trial optimization, and drug repurposing. By providing affordable, AI-powered insights, BullFrog AI enhances decision-making and efficiency across the industry—helping resource-constrained organizations do more with less while enabling larger enterprises to optimize R&D investments and streamline drug development. In addition to driving growth through its Data...
2025-04-0805 minSmall Stocks, Big MoneyLiveOne (Nasdaq: LVO) CEO Robert Ellin on Disrupting Music, Media & MonetizationHeadquartered in Los Angeles, CA, LiveOne (Nasdaq: LVO) is an award-winning, creator-first, music, entertainment, and technology platform focused on delivering premium experiences and content worldwide through memberships and live and virtual events. LiveOne's subsidiaries include Slacker Radio, PodcastOne (Nasdaq: PODC), PPVOne, CPS, LiveXLive, DayOne Music Publishing, Drumify and Splitmind. LiveOne is available on iOS, Android, Roku, Apple TV, Spotify, Samsung, Amazon Fire, Android TV, and through STIRR's OTT applications.LiveOne is a client of RedChip. Visit www.redchip.com/stocks/LVO to learn more.
2025-04-0110 minSmall Stocks, Big MoneyInside Nexalin: CEO Mark White on TBI Solutions & Expanding Market PotentialNexalin Technology is a pioneering medical technology company focused on addressing the global mental health crisis through innovative neurostimulation devices. Nexalin's products, which include the Gen-2 and newly introduced Gen-3 HALO™ Clarity devices, are non-invasive and utilize advanced frequency-based stimulation to target deep brain structures associated with various mental health disorders. These disorders include but are not limited to depression, anxiety, insomnia, PTSD, and traumatic brain injuries. Nexalin's commitment to non- pharmacological treatment options is underpinned by extensive clinical research and intellectual property protections, aiming to provide significant therapeutic benefits without adverse effects. The company's approach integrates product innovation wi...
2025-03-2513 minSmall Stocks, Big MoneyInside Knightscope (Nasdaq: KSCP): CEO William Santana Li on AI, Robotics & Crime PreventionKnightscope (Nasdaq: KSCP) is transforming public safety with cutting-edge robotics and AI technologies. From autonomous security robots to advanced detection systems, Knightscope is committed to building safer communities where you live, work, study and visit. Their long-term ambition is bold but simple: to make the United States of America the safest country in the world.Knightscope is a client of RedChip Companies. Visit RedChip.com to learn more.
2025-03-1813 minSmall Stocks, Big MoneyJupiter Neurosciences CEO Christer Rosén on Advancing Neuroinflammation Treatments & BeyondJupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage pharmaceutical company pioneering treatments for neuroinflammation and rare diseases through its proprietary resveratrol delivery platform. Its lead product, JOTROL™, offers groundbreaking bioavailability—nine times greater than traditional resveratrol formulations—enabling safe, effective treatment for CNS disorders like Alzheimer's and Parkinson's. Backed by elite research partnerships and a robust clinical pipeline, including multiple Phase 2 trials expected to launch within the next 12 months, Jupiter is also advancing a near-term direct-to-consumer revenue opportunity in nutraceuticals, positioning the company as a transformative force in both pharmaceutical and consumer health markets.Jupiter Neurosciences is a client of Red...
2025-03-1110 minSmall Stocks, Big MoneyAlliance Entertainment: Inside The Billion-Dollar Giant Powering Media Distribution GloballyAlliance Entertainment is the global leader in physical media distribution, acting as the crucial gateway between major content producers and retailers. The company partners with nearly every major film studio, music label, and video game maker, including Disney, Sony, Universal, Warner Bros., Universal Music, Sony Music, Warner Music, Microsoft, and Nintendo, to distribute their products to retailers worldwide. With over 325,000 in stock SKUs, Alliance supplies major retailers like Walmart, Amazon, and Best Buy, as well as thousands of independent stores. In fiscal 2024, Alliance generated over $1.1 billion in revenue, with more than $250 million from exclusive distribution deals. As the dominant...
2025-03-0408 minSmall Stocks, Big MoneyInside Calidi Biotherapeutics: CFO Andrew Jackson Breaks Down the Future of Oncolytic VirotherapyCalidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even p...
2025-02-2506 minSmall Stocks, Big Money60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoffrey Dow on Expanding Malaria Prevention & Beyond60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60P is a client of RedChip. Visit www.redchip.com/stocks/sxtp to learn more.
2025-02-1807 minSmall Stocks, Big MoneyElevating Fan-Owned Live Entertainment: VENU Founder & CEO J.W. Roth Shares His Disruptive ApproachVenu Holding Corporation (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery, Roth’s Seafood and Chophouse, and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience.
VENU has been...
2025-02-0412 minSmall Stocks, Big MoneyASP Isotopes CEO Paul Mann on Breakthrough Isotope Tech, Quantum Computing & 2025 Growth PlansASP Isotopes (Nasdaq: ASPI) is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing.
Visit www.redchip.com/stocks/ASPI to learn more.
ASP Isotopes (ASPI) agreed to pay RedChip Companies, Inc., a $12,500 monthly cash fee and $50,000 of Rule 144 stock...
2025-01-2807 minSmall Stocks, Big MoneyInside Enlivex: Oren Hershkovitz on Tackling Sepsis, Osteoarthritis, and Beyond with Allocetra™Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Diseases such as osteoarthritis, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.
Visit redchip.com/stocks/ENLV to learn more.
Enlive...
2025-01-0708 minSmall Stocks, Big MoneyInside Gorilla Technology: CEO Jay Chandan & Interim CFO Bruce Bower on Smart Cities & Big DataGorilla Technology Group (Nasdaq: GRRR) is a global leader in AI-based IIOT (Industrial Internet of Things) solutions with a strong emphasis on security convergence, video analytics, and big data. Leveraging over 22 years of innovation and industry expertise, Gorilla provides transformative solutions that enhance the safety, efficiency, and operational capabilities of smart cities, smart ports, smart buildings, and more. The company's proprietary technologies empower clients across both public and private sectors by offering predictive insights and robust network defense, driving the next wave of digital transformation. With a footprint spanning over seven countries and 29 granted patents globally, Gorilla Technology is...
2024-12-1718 minSmall Stocks, Big MoneyInside OKYO Pharma’s (NASDAQ: OKYO) Phase 2 Trials with CEO Dr. Gary JacobOKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions of NCP.
Visit www.redchip.com/stocks/okyo to learn more.
2024-12-0308 minSmall Stocks, Big MoneyInside VSee Health’s Telehealth Revolution: Exclusive Interview with Co-CEO Dr. Imo AisikuVSee Health is a software-as-a-service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. VSee Health's system allows a telehealth mobile app to be created or a telehealth system to be integrated into existing hospital operations in days. With a focus on patient disease state telemedicine and turnkey billing services, VSee Health has integrated an intensive care, critical care and neuro solution, powered by iDoc Telehealth Solutions, as its initial module for the VSee Health software platform. This technology encompasses a set of integrated telehealth technologies and a team of neurointensivists, neurologists, and tele-radiologists...
2024-11-2607 minSmall Stocks, Big MoneyInside Can-Fite BioPharma’s (NASDAQ: CANF) Clinical Pipeline with CEO Motti FarbsteinCan-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of NASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast...
2024-11-1905 minSmall Stocks, Big MoneyHow MUSQ ETF is Reshaping Music Investments: CEO David Shulhof ExplainsThe MUSQ Global Music Industry ETF (MUSQ) offers investors focused exposure to the growing global music industry. The fund aims to replicate the performance of the MUSQ Global Music Industry Index (MUSQIX), which rebalances quarterly and includes publicly traded companies and royalty funds with significant revenues tied to music. MUSQ provides access to key segments such as music streaming, live events and ticketing, content distribution, satellite and broadcast radio, and music equipment and technology. Launched in July 2023, the fund is positioned to benefit from the evolving digital landscape, including the rise of streaming and AI-driven content creation.
With the...
2024-11-1205 minSmall Stocks, Big MoneyThe Future of Oncology: Calidi’s Stem Cell-Based Platforms for Fighting CancerCalidi Biotherapeutics (NYSE American:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
Visit RedChip.com to l...
2024-10-2207 minSmall Stocks, Big MoneyHow Alliance Entertainment (Nasdaq AENT) is Optimizing Operations for Continued Margin ImprovementAlliance Entertainment is the global leader in physical media distribution, acting as the crucial gateway between major content producers and retailers. The company partners with nearly every major film studio, music label, and video game maker, including Disney, Sony, Universal, Warner Bros., Universal Music, Sony Music, Warner Music, Microsoft, and Nintendo, to distribute their products to retailers worldwide. With over 325,000 in stock SKUs, Alliance supplies major retailers like Walmart, Amazon, and Best Buy, as well as thousands of independent stores. In fiscal 2024, Alliance generated over $1.1 billion in revenue, with more than $250 million from exclusive distribution deals. As the dominant...
2024-10-0811 minSmall Stocks, Big MoneyThe Gold Rush of 2024: Christopher Gerteisen’s Vision for Nova Minerals and BeyondNova Minerals Limited is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project, comprised of 514 km 2 of State of Alaska mining claims, which contains multiple mining complexes across a 35 km long mineralized corridor of over 20 advanced Gold and Antimony prospects, including two already defined multi-million ounce resources, and several drill ready Antimony prospects with massive outcropping stibnite vein systems observed at surface. The 85% owned project is located 150 km northwest of Anchorage, Alaska, USA, in the prolific Tintina Gold Belt, a province which hosts an over 220 million ounce (Moz) documented gold endowment and...
2024-10-0110 minSmall Stocks, Big MoneyInterview with Founder of MUSQ Global Music Industry ETFTracking the MUSQ Global Music Industry Index (MUSQIX), the MUSQ Global Music Industry ETF (NYSE: MUSQ) includes publicly traded companies with core interests in music streaming, content and distribution, live events, satellite and broadcast radio, and music equipment and technology.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular...
2024-09-2406 minSmall Stocks, Big MoneyCEO Interview: ASP Isotopes is Commercializing New Isotope Enrichment TechnologyASP Isotopes harnesses two decades of research and development to produce a broad range of isotopes, serving the expanding needs of nuclear medicine and green nuclear energy sectors. The Company's cutting-edge technology positions it to meet critical global demands heightened by recent geopolitical dynamics.
With cold commissioning completed at its first plant and several strategic off-take agreements in place, ASP Isotopes is on track to become a leader in non-nuclear isotope supply by 2028. Noteworthy agreements include a $27 million annual contract with BRICEM for Molybdenum-100, a $3.8 million annual deal for Carbon-14 with a Canadian firm, and a significant $9 million agreement...
2024-09-1709 minSmall Stocks, Big MoneyCEO Interview: Discover How OKYO Pharma is Targeting the Multi-Billion-Dollar Dry Eye Disease MarketOKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials...
2024-09-0310 minSmall Stocks, Big MoneyLearn Why Soligenix has Received $60M+ in Non-Dilutive Funding From the US Government: CEO InterviewSoligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™ (synthetic hypericin), a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and has reached agreement with the European Medicines Agency (EMA) on the key design components of a confirmatory Phase 3 pivotal study while discussions with the US Food & Drug Administration rema...
2024-08-2010 minSmall Stocks, Big MoneyPioneering New Osteosarcoma and Breast Cancer Treatments: Exclusive Interview with OS Therapies' CEOOS Therapies (OSTX), a clinical stage biopharmaceutical company, is at the forefront of
developing innovative treatments for Osteosarcoma (OS), breast cancer and other
solid tumors. With a dedicated focus on addressing the unmet need for new cancer
treatments in children and young adults, the company is making significant strides
in tackling the complexities of OS, a rare but aggressive bone cancer predominantly
affecting individuals under 40 years of age.
The company's primary initiative revolves around its lead product candidate, OSTHER2 (OST31-164), which is poised to revolutionize the treatment landscape for OS,
breast cancer, and other HER2 expressing cancers. This...
2024-08-1311 minSmall Stocks, Big MoneyCEO INTERVIEW: American Resources Corporation's Unique Ability to Refine Critical ElementsAmerican Resources Corp. (NASDAQ: AREC) is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. American Resources has established a nimble, low-cost business model centered on...
2024-08-0606 minSmall Stocks, Big MoneyGreenPower Leverages Government Mandates and Funding to Boost Zero-Emission School Bus Line GrowthGreenPower Motor Company is advancing the adoption of electric vehicles (EVs) by making all-electric buses and trucks affordable, durable and easy to deploy. GreenPower offers commercial vehicles for the movement of goods and people that are built from the ground up to be all-electric and are never converted. This “clean sheet” design ensures a safe, sustainable and sensible form of transportation, allowing for optimal placement of the battery and propulsion systems, increasing the overall vehicle strength and significantly enhancing the battery weight distribution compared to other EVs. With more than 700 GreenPower all-electric, purpose-built, zero-emission vehicles delivered, a substantial order pipe...
2024-07-3005 minSmall Stocks, Big MoneyDiscover Nexalin's Neurostimulation Device Targeting Mental Health DisordersNexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation de...
2024-07-2311 minSmall Stocks, Big MoneyBiotricity CEO, Waqaas Al-Siddiq, on New Heart Health Innovations & the Future of Cardiac CareBiotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets.
Visit btcyinfo.com to learn more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are...
2024-07-1609 minSmall Stocks, Big MoneyHope for Lung Cancer Patients: Cypath Lung Test's ImpactbioAffinity Technologies, Inc. (NASDAQ: BIAF) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung , is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services , a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio.
RedChi...
2024-07-0910 minSmall Stocks, Big MoneyAlta Global Group: Converting MMA fans into Participants. An Interview with CEO Nick LangtonIn this exclusive interview, we sit down with the CEO of Alta Global Group (MMA) to uncover how they're transforming the world of MMA training. Discover their innovative strategies to engage 640 million MMA fans worldwide. Learn about their unique business model, partnerships with legends like Conor McGregor, and their vision for the future of mixed martial arts training.
Topics Covered:
Overview of Alta Global Group's mission and business model
Insights into partnerships with top MMA stars and coaches
How they are converting fans into active participants
Exclusive look into their subscription-based training programs
The future of MMA training and...
2024-07-0215 minSmall Stocks, Big MoneyExploring Can-Fite BioPharma's Groundbreaking Drugs: Piclidenoson and NamodenosonCan-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company has 2 drug candidates in advanced stages of development, Piclidenoson for the treatment of psoriasis and Namodenoson for the treatment of advanced liver cancer. For each of the drugs, a registration plan has been agreed with both the U.S. FDA and the European Medicines Agency (EMA) and enrollment of patients for a pivotal Phase III clinical study is ongoing for liver cancer and underway for psoriasis. Namodenoson also...
2024-05-1408 minSmall Stocks, Big MoneyUnlocking Hope: The BioVie Journey in Neurodegeneration and Liver DiseaseBioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
BioVie is poised for significant catalysts in 2023, including data read out from its Alzheimer’s Phase 3 trial, expected in Q4 2023, as well as interim data read outs from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other efforts underway that may create additional catalysts and will be announced...
2024-04-3012 minSmall Stocks, Big MoneyAI Solutions in the Online CBD Industry: A 1606 Corp. Perspective1606 Corp. (OTC: CBDW) stands at the forefront of technological innovation in the online CBD industry. With a clear mission to revolutionize customer service in the digital marketplace, 1606 Corp. leverages state-of-the-art artificial intelligence (AI) solutions to address the significant challenges faced by consumers in the online CBD sector. Recognizing the unique needs of each business, 1606 Corp. focuses on collaboration and customization in providing customer service solutions to online CBD retailers. This approach allows the company to develop smart, tailored solutions that cater to the immediate needs of their clients while laying a foundation for long-term success. 1606 Corp. empowers both large...
2024-04-2310 minSmall Stocks, Big MoneySpectaire Holdings (Nasdaq: SPEC) Launches AireCore System for Emissions Management!Spectaire Holdings (Nasdaq: SPEC) represents a pioneering leap in environmental technology with its flagship AireCore system, a game-changer in emissions measurement and management. This innovative system, which includes a cutting-edge emissions measurement device, encrypted cloud storage, and intuitive desktop/mobile applications, offers a comprehensive solution for tracking and reducing carbon footprints at a fraction of the cost of traditional methods.
With a business model combining upfront low-cost hardware sales with recurring service revenues, Spectaire is set to democratize access to mass spectrometry, mirroring the transformative shifts seen from mainframes to laptops and landlines to cellular phones.
2024-04-0912 minSmall Stocks, Big MoneyGenetic Technologies: Innovating Healthcare with Genomics-based Cancer PredictionsGenetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person’s risk in up to 70% of annual mortalities and morbidities before onset. The Multi-Risk test, along with integration of recently acquired DNA based products, underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage. GENE’s expanding product portfolio includes more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In a...
2024-04-0209 minSmall Stocks, Big MoneyUnlocking Growth: Exploring LOBO EV's Path to Market Leadership in E-Bikes and EVsLOBO EV presents an attractive value proposition underpinned by its strategic growth initiatives and solid performance across key segments. With an established track record and a focus on becoming an OEM and ODM leader in the intelligent urban tricycles and off-highway four-wheeled electric vehicles (EVs) market over the next decade, LOBO EV is poised for significant growth. The Company is executing a robust strategy that includes continuous innovation and new product launches, enhancing customer relationship management, diversifying marketing approaches, and stringent cost control measures. These efforts, aimed at capitalizing on the burgeoning demand for e-bikes, positions LOBO EV for...
2024-03-2608 minSmall Stocks, Big MoneyEnlivex's (NASDAQ:ENLV) Allocetra™: Breakthrough Macrophage Reprogramming TherapyEnlivex presents a compelling investment opportunity in the biopharmaceutical sector with its innovative approach to treating life-threatening and debilitating conditions through macrophage reprogramming. The company's leading product, Allocetra™, is a groundbreaking, off-the-shelf cost-effective cell therapy platform designed to reset the body's immune cells (macrophages) to their optimal functioning state. This technology addresses a critical need for rebalancing the immune system, offering potential treatments for a range of inflammatory and autoimmune diseases with high unmet medical needs. With macrophages playing a vital role as the body's first line of defense, Enlivex's focus on converting these cells from a "disease setting" ba...
2024-03-1913 minSmall Stocks, Big MoneyBiotricity (NASDAQ: BTCY) Transforming Cardiac Care: Innovative Remote Monitoring SolutionsBiotricity is revolutionizing cardiac care with its cutting-edge remote diagnostic and monitoring solutions that cater to a $35 billion total addressable market opportunity. By integrating advanced hardware and proprietary software, Biotricity has established a new paradigm in cardiac care. The Company’s robust technology platform and product ecosystem, featuring FDA-cleared smart cardiac monitors, coupled with a comprehensive cloud ecosystem, ensure seamless management of patient health across all stages of cardiac care. Utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by a remarkable 99.2% retention rate and an LTV/CAC ratio of 9.
Biotricity re...
2024-03-1211 minSmall Stocks, Big MoneyUnlocking Growth: Lytus Technologies - Your Next Nasdaq Investment Opportunity in Digital & Healthcare Innovation!Lytus Technologies, a dynamic platform services company with a robust presence across India, boasts over four million active users, leveraging its strategic business model focused on the distribution of linear content streaming/telecasting services and the development of cutting-edge technology products, including telemedicine. With a subscriber base rooted in more than one million connections, Lytus is at the forefront of India’s digital transformation, providing unparalleled streaming and internet services through a sophisticated, proprietary unified technology platform. The Company is executing plans to expand into key markets globally and consolidating its subscriber base for future technological advancements in telemedicine an...
2024-03-0519 minSmall Stocks, Big MoneyBiotricity (NASDAQ: BTCY) Revolutionizing Cardiac Care: Meet biotricity - Leading Remote Patient Monitoring TechnologyBiotricity is a pioneering medical technology company delivering a full suite of remote diagnostic and remote patient monitoring hardware solutions which integrate with powerful and proprietary software solutions to deliver state-of-the-art cardiac care to patients. Leveraging a technology-as-aservice model, our innovative product portfolio, which includes our FDAcleared Bioflux® and Biotres devices, addresses a total addressable marketof $35 billion.
Strategic contracts with leading Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) position us for rapid market penetration and growth. At the core of our expansion strategy is the advancement of our proprietary AI technology to deliver award-winning, best-in-class p...
2024-02-2711 minSmall Stocks, Big MoneyXcel Brands (NASDAQ:XELB): Leading the Social Commerce RevolutionXcel Brands is a pioneering force in the convergence of shopping, entertainment, and social media and expects to generate $18 million in top-line royalty revenue in 2024. Based on the recent sale of 70% interest in its Isaac Mizrahi brand, which sold for six times royalty revenue, Xcel is trading for a greater than 75% discount to its intrinsic value, presenting tremendous potential upside for investors. Social commerce is expected to drive 20% of all US online sales by 2026, and Xcel is perfectly positioned to capture a significant market share with its proven approach to increasing conversion rates that significantly outperforms traditional digital marketing...
2024-02-2011 minSmall Stocks, Big Money1606 Corp. (OTC: CBDW): Revolutionizing CBD Customer Service with AI Innovation1606 Corp. (OTC: CBDW) stands at the forefront of technological innovation in the online CBD industry. With a clear mission to revolutionize customer service in the digital marketplace, 1606 Corp. leverages state-of-the-art artificial intelligence (AI) solutions to address the significant challenges faced by consumers in the online CBD sector. Recognizing the unique needs of each business, 1606 Corp. focuses on collaboration and customization in providing customer service solutions to online CBD retailers. This approach allows the company to develop smart, tailored solutions that cater to the immediate needs of their clients while laying a foundation for long-term success. 1606 Corp. empowers both large...
2024-02-1312 minSmall Stocks, Big MoneyMeet Shalabh Gupta, CEO of Unicycive Therapeutics (NASDAQ: UNCY)We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, we have two programs focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies:Â Oxylanthanum Carbonate (OLC), for the treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494 for the treatment of acute kidney injury.
RedChip Companies, Inc. r...
2024-01-3023 minSmall Stocks, Big MoneybioAffinity Technologies: Exploring the Future of Cancer CarebioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD’s purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Com...
2023-12-2616 minSmall Stocks, Big MoneyMeet Maria Zannes: CEO of BioAffinity Technologies (NASDAQ: BIAF)bioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD’s purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Com...
2023-12-1919 minSmall Stocks, Big MoneyInnovation in Flight: Mobilicom's End-to-End Solutions for Drone CybersecurityMobilicom provides cybersecurity and robust solutions for drones and robotics. The Company is positioned to capture market leadership as the top end-to-end provider of hardware and software solutions in the rapidly growing defense and commercial drone and robotics market, a total addressable market expected to reach $8.5 billion by 2026. The Ukraine-Russia conflict is expected to further drive demand for Mobilicom’s drone cybertech solutions. The Company’s large portfolio of field-proven technologies includes cybersecurity, software, and hardware solutions that power, connect, guide, and secure drones and robotics. Through deployments across 16 countries with over 50 customers, Mobilicom generates revenues from hardware and soft...
2023-12-0507 minSmall Stocks, Big MoneyHow Royalty Management Transforms Undervalued AssetsRoyalty Management Holding Corporation identifies and invests in highly undervalued assets in either growing or transitioning marketplaces in order to obtain an ongoing royalty or cashflow stream in the project. RMCO finds undervalued assets that are either under utilized, undeveloped or at an inflection point in their life cycle. Visit RMCOinfo.com to learn more. bit.ly/3FQhAku
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to...
2023-11-2111 minSmall Stocks, Big MoneyMeet Kirk Taylor: CFO of Royalty Management Holding Corporation (NASDAQ: RMCO)Royalty Management Holding Corporation (NASDAQ:RMCO) is a royalty company building shareholder value to benefit both our shareholders and communities by acquiring and developing high value assets in a sustainable market environment.Our model is to acquire and structure assets, equity interests, royalty interests and cashflow streams around assets that can support the communities by monetizing the assets with a future focus.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but...
2023-11-1411 minSmall Stocks, Big MoneyMeet Paul Mann: CEO & Chairman of ASP IsotopesASP Isotopes, a leading isotope enrichment company, harnesses cutting-edge technology developed over two decades in South Africa to enrich isotopes of elements and molecules with low atomic masses. Many of these elements are impractical to enrich using conventional methods like centrifuges. ASP Isotopes' primary mission is to produce and market highly enriched isotopes, catering to the healthcare and technology sectors. For more information about our groundbreaking work, please visit https://bit.ly/ASPIinfo."
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on...
2023-11-0710 minSmall Stocks, Big MoneyMeet Denton Peng: CEO & Chairman of SPIDelivering competitive, clean energy solutions to customers for more than 15 years, SPI is an established renewable energy player with global operations in key markets in Asia, Australia, North America, and Europe. SPI has assets of $230 million and currently trades for a fraction of its trailing 12-month revenue of $197 million, a significant discount to peer group multiples. SPI is expected to be net profitable in 2023 with full year net income guidance of $29 million to $36 million on revenues of $250 million to $300 million. To unlock additional shareholder value, SPI completed an IPO spinoff of Phoenix Motor (Nasdaq: PEV) in 2022 (currently owns 25%) and...
2023-10-3115 minSmall Stocks, Big MoneyMeet Simon Morriss: CEO of Genetic Technologies (NASDAQ: GENE)Genetic Technologies Limited (Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products...
2023-10-2407 minSmall Stocks, Big MoneyMeet Jonathan Guarino: CFO of Soligenix (NASDAQ: SNGX)Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Learn more at https://www.redchip.com/stocks/SNGX https://bit.ly/43TJ8ik
...
2023-10-1711 minSmall Stocks, Big MoneyMeet Dr. Chris Schaber: CEO & President of Soligenix (NASDAQ: SNGX)Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Learn more at https://www.redchip.com/stocks/SNGX https://bit.ly/43TJ8ik
...
2023-10-1019 minSmall Stocks, Big MoneyMeet Vu Truong, Founder and CEO of Aridis Pharmaceuticals (OTC: ARDS)Aridis Pharmaceuticals (OTC: ARDS) is advancing multiple clinical stage monoclonal antibodies (mAbs) targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human...
2023-10-0314 minSmall Stocks, Big MoneyEverything Blockchain: Blending Database Security & Blockchain TechnologiesEverything Blockchain (OTC: EBZT) is a key player in building the future where every transaction is trusted and blockchain is used to meet ESG goals, support cities of the future, build and control the transparency of supply chains and ensure the rights of data ownership sustain forever. The Company’s patent-pending advances in blockchain engineering deliver the essential elements needed for real-world business use: speed, security, and energy efficiency. Visit EBZTinfo.com to learn more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are ba...
2023-08-2514 minSmall Stocks, Big MoneySharps Technology: Targeting Niche, Multi-Billion-Dollar MarketsSharps Technology (NASDAQ: STSS) is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q3 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Ph...
2023-08-2410 minSmall Stocks, Big MoneyContinental Lithium: Addressing the Rapidly Increasing Global Demand for LithiumFounded in 2017, Continental Lithium commenced small-scale mining in collaboration with artisanal miners in 2018. Over the last five years, the underlying assets acquired by Continental Lithium have produced approximately 15,000 metric tons of lithium concentrate. The Company has plans to develop its lithium and rare earth mineral assets and substantially increase its production for export to the U.S., Europe and Asia. Continental Lithium currently owns 100% interest in 26 minerals licenses covering 61,500 hectares which were acquired from the Nigerian Mining Cadastre Office. 15 of the 26 licenses cover 45,900 hectares for lithium and other pegmatite-hosted mineralization of tin, tantalum, niobium and gemstones. In addition, the...
2023-08-2314 minSmall Stocks, Big MoneySoligenix: Late-Stage Biopharma Addressing a $2 Billion OpportunitySoligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study...
2023-08-2211 minSmall Stocks, Big MoneyGraphex Group: Top-10 Global Producer of Graphite AnodesGraphex Group (NYSE American: GRFX) is a global leader in the mid-stream deep processing of natural spherical graphite and graphene-related products, key components of the Lithium-ion (Li-ion) batteries used in Electric Vehicles (EVs), renewable energy storage systems, and other use cases. With over a decade of production experience operating at commercial-scale volumes and quality, Graphex is currently producing over 10,000 metric tons of specialized spherical graphite anode materially annually and holds patents in areas including products, production methods, machinery design, and environmental protection. With a strategy to expand its operations to support energy transition and electrification efforts worldwide, Graphex is...
2023-08-2118 minSmall Stocks, Big MoneyMeet Shahar Hania, CEO of Rail Vision (NASDAQ:RVSN)Rail Vision (NASDAQ: RVSN) is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electro-optic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions. Tailormade to meet every customer’s specific needs, the systems are available for Main Lines and Shunting Yards, as well as Light Rail Vehicles (LRVs) operating in urban environments. In addition, Rail Vision o...
2023-08-1805 minSmall Stocks, Big MoneySplash Beverage: Ground-Floor Opportunity with High-Growth Beverage BrandsSplash Beverage Group (NYSE American: SBEV), an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrĂas, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch int...
2023-08-1706 minSmall Stocks, Big MoneySoligenix: A Late-Stage Biopharma Pioneer Tackling Rare Diseases with Unmet NeedsSoligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Learn more at https://www.redchip.com/stocks/SNGX
RedChip Co...
2023-08-1605 minSmall Stocks, Big MoneyASP Isotopes: Advanced Materials Company Targeting Isotope ProductionASP Isotopes (NASDAQ: ASPI) is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company is initially focused on commercializing Molybdenum 100, which has the potential to replace Molybdenum 99, a commonly used product in the diagnostic imaging market, and Carbon-14, the most frequently used radiolabel for drug discovery, drug metabolism, and pharmacokinetics. Visit ASPIinfo.com to learn more.
RedChip Companies, Inc. research reports, company...
2023-08-1511 minSmall Stocks, Big MoneyAmerican Resources Corporation (NASDAQ: AREC): Focusing On Critical and Rare Earth Minerals for the Electrification MarketAmerican Resources Corp. (NASDAQ: AREC) is building one of the most unique growth platforms to strategically align old-world, legacy assets with a more modern economy. The Company is focused on extracting and processing metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in Kentucky, Indiana, and West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. Visit ARECinfo.com to learn more.
RedChip Companies, Inc. research reports...
2023-08-1408 minSmall Stocks, Big MoneyMeet Curt Marvis, The Man Behind QYOU Media. (OTCQB: QYOUF)QYOU Media (OTCQB: QYOUF) has added to the depth and breadth of its products and capabilities throughout 2022. With five active channels now in India and the addition of ChtrSocial in India and Q Studios in the US, QYOU Media is rapidly advancing its push towards driving increased audience size and strong revenue growth in 2023 and beyond. Building on a solid foundation with accelerating momentum among major advertisers, QYOU Media is ideally positioned for long-term success. Visit QYOUFinfo.com to learn more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications...
2023-08-1115 minSmall Stocks, Big MoneyAridis Pharma Founder & CEO Discusses Upcoming Milestones for its Late-Stage PipelineAridis (OTC: ARDS) is revolutionizing how we treat infectious diseases through its unique technology platforms, which can quickly detect human-derived mAbs to treat infectious diseases. The Company's transformative approach utilizes a patient's own immune system to identify mAbs capable of fighting infections and underpins multiple late-stage programs. In January, Aridis announced positive top-line data from the first of two Phase 3 studies of its lead candidate, AR-301, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). In March, Aridis announced positive top-line data from its Phase 2a trial in cystic fibrosis, meeting primary and second endpoints...
2023-08-1008 minSmall Stocks, Big MoneyInterview with Sixty Degrees Pharma (Nasdaq: SXTP) CEO Geoff DowLearn about Sixty Degrees Pharma (Nasdaq: SXTP) from CEO Geoff Dow. In this exclusive interview with Dow, gain insight into the company's mission to develop and commercialize new therapies for a range of infectious diseases, including its FDA-approved malaria preventative treatment ARAKODA® and the Company's current pipeline development programs for Tafenoquine and Celgosivir targeting COVID-19, fungal, tick-borne, and other viral diseases. Learn more about this game-changing small-cap stock by visiting SXTPinfo.com today.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on d...
2023-08-0911 minSmall Stocks, Big MoneyBioVie (NASDAQ: BIVI): Poised for Significant Catalysts in 2023BioVie is poised for significant catalysts in 2023, including data read out from its
Alzheimer’s Phase 3 trial, expected in Q3 2023, as well as interim data read outs
from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other efforts underway that may create additional catalysts and will be announced publicly when the Company deems appropriate. Learn more at: https://www.redchip.com/stocks/bivi
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be...
2023-08-0811 minSmall Stocks, Big MoneyMeet Vin Singh, Founder & CEO of Bullfrog AI (NASDAQ:BFRG)Meet the Founder & CEO of Bullfrog AI (NASDAQ:BFRG) Vin Singh as he delves deep into his personal life and how those choices help shape the precision medicine company that uses AI and machine learning to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not...
2023-08-0712 minSmall Stocks, Big MoneyThe Mark Jensen Story – From Wall Street Banker to Indiana Battery Recycler - American Resources Corporation (NASDAQ:AREC)Meet the CEO of American Resources Corporation (NASDAQ:AREC) Mark Jensen as he delves deep into his personal life and how those choices help shape the building of one of the most unique growth platforms to strategically align old-world, legacy assets with a more modern economy.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information...
2023-08-0410 minSmall Stocks, Big MoneyRail Vision (NASDAQ: RVSN): Potentially Preventing Catastrophe’s Before They OccurRail Vision (NASDAQ: RVSN) is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electro-optic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions. Tailormade to meet every customer’s specific needs, the systems are available for Main Lines and Shunting Yards, as well as Light Rail Vehicles (LRVs) operating in urban environments. In addition, Rail Vision o...
2023-08-0306 minSmall Stocks, Big MoneyAmerican Resources Corporation (NASDAQ: AREC): How this Company Turns Trash to TreasureAmerican Resources Corp. (NASDAQ: AREC) is building one of the most unique growth platforms to strategically align old-world, legacy assets with a more modern economy. The Company is focused on extracting and processing metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in Kentucky, Indiana, and West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. Visit ARECinfo.com to learn more.
RedChip Companies, Inc. research reports...
2023-08-0204 minSmall Stocks, Big MoneySPI Energy Group (NASDAQ: SPI): Unlocking Shareholder Value Under the SunDelivering competitive, clean energy solutions to customers for more than 15 years, SPI Energy (NASDAQ: SPI) is an established renewable energy player with global operations in key markets in Asia, Australia, North America, and Europe. Since 2006, SPI has been a leading solar project developer, delivering competitive, clean energy solutions to customers across the U.S. and globally. The company has completed rooftop solar installations for retail giant Costco, LA’s famed Staples Center, home of the Lakers, and Sacramento’s Golden1 Credit Union Center, home of the Kings, amongst other notable projects. Visit https://www.spigroupsinfo.com/ to learn more.
2023-08-0105 minSmall Stocks, Big MoneyBiovie (NASDAQ: BIVI): Innovating Potential Alzheimer’s and Parkinson’s TreatmentBioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzhei...
2023-07-3107 minSmall Stocks, Big MoneyHow Zomedica (NYSE American: ZOM) Is Changing the Veterinary Industry with Its Cutting-Edge Diagnostics and TherapeuticsZomedica (NYSE American: ZOM) is revolutionizing veterinary health care with a focus on addressing unmet needs through its expanding product portfolio of innovative diagnostics and medical devices designed to improve pet health as well as productivity and practice profitability for veterinarians. With modest cash burn and a strong balance sheet, including $156 million cash, cash equivalents, and available-for-sale securities as of September 30, 2022, Zomedica is well-positioned to fund both organic growth and acquisitions. Visit ZomedicaInfo.com to learn more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web...
2023-07-2807 minSmall Stocks, Big MoneyEnd of the Exponential Equity Growth Era? Where to Invest NextListen to this episode!
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy...
2023-07-2707 minSmall Stocks, Big MoneyContinental Lithium: Addressing the Rapidly Increasing Global Demand for LithiumFounded in 2017, Continental Lithium commenced small-scale mining in collaboration with artisanal miners in 2018. Over the last five years, the underlying assets acquired by Continental Lithium have produced approximately 15,000 metric tons of lithium concentrate. The Company has plans to develop its lithium and rare earth mineral assets and substantially increase its production for export to the U.S., Europe and Asia. Continental Lithium currently owns 100% interest in 26 minerals licenses covering 61,500 hectares which were acquired from the Nigerian Mining Cadastre Office. 15 of the 26 licenses cover 45,900 hectares for lithium and other pegmatite-hosted mineralization of tin, tantalum, niobium and gemstones. In addition, the...
2023-07-2607 minSmall Stocks, Big MoneyReviva Pharma (NASDAQ: RVPH) Charting Success: Reviva Pharma's Journey from phase 3 to Potential NDA filingReviva (Nasdaq: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for Q3 2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and...
2023-07-2506 minSmall Stocks, Big MoneyUnlocking Precision Medicine: BullFrog AI's (Nasdaq: BFRG) Trailblazing Use of AI to Predict Therapeutic Success and Transform Drug DevelopmentBullFrog AI (Nasdaq: BFRG) is a precision medicine company using AI and machine learning to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics. Learn more at BFRG...
2023-07-2409 minSmall Stocks, Big MoneyQYOU Media (OTCQB: QYOUF) Media Mavericks: The Investment Potential of QYOU Media; India's Exponentially Growing Content PowerhouseQYOU Media (OTCQB: QYOUF) has added to the depth and breadth of its products and capabilities throughout 2022. With five active channels now in India and the addition of ChtrSocial in India and Q Studios in the US, QYOU Media is rapidly advancing its push towards driving increased audience size and strong revenue growth in 2023 and beyond. Building on a solid foundation with accelerating momentum among major advertisers, QYOU Media is ideally positioned for long-term success. Visit QYOUFinfo.com to learn more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications...
2023-07-2009 minSmall Stocks, Big MoneySharps Technology, Inc. (NASDAQ: STSS): Sustainable Solutions, Profitable Investments: Inside the No Waste Syringe RevolutionSharps Technology (Nasdaq: STSS) is a medical device company addressing global issues while engineering a safer future for healthcare providers and people everywhere through compassionate innovation. Sharps Provensa™ is the Company’s premier line of smart safety syringes that eliminate accidental needlestick injuries, prevent improper needle reuse, and reduce wasted medicine and vaccines—while retaining the intuitive simplicity of traditional syringes. Visit STSSinfo.com to learn more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be...
2023-07-1906 minSmall Stocks, Big MoneyGraphex Group Ltd. (NYSE American: GRFX) Unearthed: Unveiling the Hidden Powerhouse – The Podcast Exploring Graphex Groups Dominance in the Graphite MarketGraphex Group (NYSE American: GRFX) is a global leader in the mid-stream deep processing of natural spherical graphite and graphene-related products, key components of the Lithium-ion (Li-ion) batteries used in Electric Vehicles (EVs), renewable energy storage systems, and other use cases. With over a decade of production experience operating at commercial-scale volumes and quality, Graphex is currently producing over 10,000 metric tons of specialized spherical graphite anode materially annually and holds patents in areas including products, production methods, machinery design, and environmental protection. With a strategy to expand its operations to support energy transition and electrification efforts worldwide, Graphex is...
2023-07-1811 minSmall Stocks, Big MoneyLantern Pharma (NASDAQ: LTRN): Investing in Tomorrow's Cures: Unveiling the Power of AI Drug Development PlatformsLantern Pharma (Nasdaq: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The Company’s proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern Pharma has accelerated the development of its growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, Lantern Pharma’s newly developed drug progr...
2023-07-1713 min